Podcasts about american society

From Season 2 – Do you have generational biases at work? Dr. Carrie Spell-Hansson shares how you can start challenging assumptions and having more meaningful conversations with colleagues across generations. Recorded at EA Ignite Fall 2023 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Peter Lobasso, vice president and general counsel for the American Society of Travel Advisors (ASTA), talks with James Shillinglaw of Insider Travel Report at last month's ASTA Travel Advisor Conference in San Diego about ASTA's Verified Travel Advisor (VTA) program, what it includes, how many have passed it and what it means to be a VTA. Lobasso also discusses other ASTA initiatives such as its efforts to support cruise lines that have eliminated non-commissionable fares (NCFs). For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox. 

Dr. Ashok K. Shetty is a University Distinguished Professor in the Department of Cell Biology and Genetics and Associate Director of the Institute for Regenerative Medicine at Texas A&M University, Naresh Vashisht College of Medicine. He is developing treatments for neurological and neurodegenerative disorders using stem cells and stem cell-derived products, such as extracellular vesicles. These are tiny vesicles secreted by stem cells that carry microRNAs and proteins. Once they make their way into the brain, they can induce beneficial changes in neural cells to improve brain function. Science takes up a lot of Ash's time, but when he's able to get a moment to himself, he enjoys spending time with family, cycling on a stationary bicycle, playing brain games like Sudoku, and going out to see movies at the theater. Ash earned his Ph.D. in Neuroscience from the All India Institute of Medical Sciences in New Delhi, and he completed postdoctoral research at Montana State University and Duke University. Afterward, he joined the faculty at Duke University in the Division of Neurosurgery. He joined the faculty at Texas A&M University College of Medicine in 2011. In 2024, he was honored with the University Distinguished Professor Award from Texas A&M University, and he has also received the College of Medicine's Senior Research Excellence Award. In addition, Ash is a Fellow of the American Association for the Advancement of Science and the American Society for Neural Transplantation and Repair. He has received the Research Career Scientist Award from the United States Department of Veterans Affairs, has been recognized among the "World's Top 1% of Scientists" across all scientific fields, and he was the 2025 honoree of Fast Company's World Changing Ideas. In this interview, Ash shares details about his life and his work in science.

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Mark Meader, executive vice president-corporate of the American Society of Travel Advisors (ASTA), talks with James Shillinglaw of Insider Travel Report at last month's ASTA Travel Advisor Conference in San Diego about ASTA's priorities over the past year and in the future. Meader also talks about why ASTA's has also focused on corporate travel and corporate agencies. For more information, visit www.asta.org. All our Insider Travel Report video interviews are archived and available on our Youtube channel (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.

In this episode of the DermSurgery Digest, you'll hear in-depth summaries and expert commentary on select cosmetic and general dermatology articles featured in the June 2026 issue of Dermatologic Surgery. Featured contributors Isabela Jones, MD, and George Hruza, MD, MBA, share key insights and perspectives on the articles: Photographic Assessment of Cosmetic Outcome in Postsurgical Facial Scars Favors Rapidly Absorbable Polyglactin 910 Over Fast Absorbing Gut: A Blinded Randomized Clinical TrialRegenerative Aesthetics: Present Advances and Emerging Strategies for Optimized Tissue HealthDoes Prior Treatment With Facial Injectables Increase the Risk of Rhytidectomy Complications?Safety and Efficacy of a Multi-use Neurotoxin Protocol in Academic SettingsThis podcast is hosted by Naomi Lawrence, MD, Digital Content Editor for Dermatologic Surgery, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.The remaining cosmetic and general dermatology articles from the June issue are highlighted in a companion episode, Rapid Pearls, publishing on June 19, 2026.We welcome your feedback. Please contact communicationstaff@asds.net.

In this episode of the DermSurgery Digest, you'll hear in-depth summaries and expert commentary on select surgical oncology and reconstruction articles featured in the June 2026 issue of Dermatologic Surgery. Featured contributors Tara Jennings, MD, and Bradley Merritt, MD, share key insights and perspectives on the articles: Updates for Management of Merkel Cell Carcinoma of the Head and Neck: A Systematic ReviewThe CLASS Project: A Proof-of-Concept Machine Learning-Driven Complexity Level Algorithm for Surgical Scheduling in Mohs Micrographic SurgeryPharmacologic Methods to Reduce Postoperative Bleeding During the First Stage of the Interpolated Forehead Flap Repair: A Systematic ReviewThis podcast is hosted by Naomi Lawrence, MD, Digital Content Editor for Dermatologic Surgery, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.The remaining surgical oncology and reconstruction articles from the June issue are highlighted in a companion episode, Rapid Pearls, publishing on June 19, 2026.We welcome your feedback. Please contact communicationstaff@asds.net.

Wann haben Sie das letzte Mal etwas Neues gelernt?War das Lernen geplant und strukturiert - also sogenanntes “formales Lernen”? Oder ist es eher aus dem Arbeitsalltag, beim Ausprobieren, Beobachten und im Austausch mit anderen entstanden - sogenanntes “informelles Lernen”?Wie zufrieden sind Sie mit dem Lernergebnis? Und woran messen Sie das überhaupt?Spätestens die Integration von künstlicher Intelligenz in den Arbeitsalltag zeigt: Lernen - und damit auch die Metakompetenz des “Lernen lernens” ist in unserer volatilen Arbeitswelt zu einer branchenübergreifenden Schlüsselkompetenz geworden.Doch wie können wir das Lernen noch besser erlernen?In dieser Folge von New Work Meets Science stellt sich Dr. Theresa Fehn gemeinsam mit Dr. Julian Decius die Frage, wie formales, informelles und selbstreguliertes Lernen sinnvoll zusammenspielen können und warum keine dieser Lernformen für sich allein die Lösung ist.Eine Folge über die vielleicht wichtigste Fähigkeit der Zukunft – und darüber, wie Organisationen die richtigen Bedingungen hierfür schaffen können.Viel Spaß beim Hören!⁠BlackBox/Open im Web⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BlackBox/Open bei LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BlackBox/Open bei Instagram⁠⁠⁠⁠⁠⁠⁠Links & Quellen:Kirkpatrick-Modellhttps://assets.td.org/m/4a306d561507658e/original/TECHNIQUES-FOR-EVALUATING-TRAINING-PROGRAMS.pdfDonald L. Kirkpatrick (1959, 1960). Techniques for evaluating training programs. Journal of the American Society of Training Directors, 13, 21–26.Erweiterung des Kirkpatrick Modells: return of expectations (ROE)James D. Kirkpatrick, & Wendy Kayser Kirkpatrick (2009). The Kirkpatrick Four Levels: A fresh look after 50 years (1959–2009). Kirkpatrick Partners.ProMESPritchard, R. D. (1990). Measuring and improving productivity: A practical guide. Praeger.Quellenangaben zu Werken von Julian Decius:Die Schattenseiten des informellen Lernens:https://www.cambridge.org/core/journals/industrial-and-organizational-psychology/article/doubleedged-sword-of-informal-learning-catalyzing-or-undermining-sustainability/97697F3A5D08BCA84522AA2C9397F842Lorber A, Decius J. The double-edged sword of informal learning: Catalyzing or undermining sustainability? Industrial and Organizational Psychology. 2025;18(4):512-517. doi:10.1017/iop.2025.10039Paradoxa im arbeitsbezogenen Lernen:https://www.researchgate.net/publication/383503791_Paradoxes_in_work-related_learning-and_how_they_are_perceived_by_practitionersPaulsen, H., Kortsch, T. & Decuis, J. (2024). Paradoxes in work-related learning—and how they are perceived by practitioners. Gruppe. Interaktion. Organisation (GIO). Advance online publication. https://doi.org/10.1007/s11612-024-00755-3Metaanalyse zur Untersuchung des Kirkpatrickmodels:https://journals.aom.org/doi/abs/10.5465/AMPROC.2023.17041abstractDecius J., Graßmann, C., & Creon, L. (2023). Building bridges between work-related learning approaches: Insights from a secondary meta-analysis. Academy of Management Proceedings, 2023(1), 17041. https://doi.org/10.5465/AMPROC.2023.17041abstract.Hogrefe Reihe der Personalpsychologie: Lernen in Unternehmen: Formal, informell, selbstreguliert. (best practices)https://www.hogrefe.com/at/shop/lernen-in-unternehmen-97174.htmlKortsch, T., Decius, J., & Paulsen, H. (2024). Lernen in Unternehmen: Formal, informell, selbstreguliert. Hogrefe.

Sixty thousand people a year get a procedure that could change their pain forever...and most have never heard of it.In this episode of Real Things Living, Brigitte Cutshall sits down with Dr. Steven Falowski, a neurosurgeon with nearly 20 years of experience who is helping lead the charge against chronic pain — without opioids. Dr. Falowski breaks down how spinal cord stimulation has evolved from bulky external battery packs to quarter-sized implants that quietly re-train your nervous system to stop feeling pain. From spine injuries and arthritis to migraines and post-surgical recovery, this conversation opens the door to a world of solutions most patients don't even know exist.3 Takeaways:(1) Pain is more common than heart disease, cancer, and diabetes combined — yet the tools to treat it effectively remain largely unknown to the public.(2) Spinal cord stimulators don't just block pain anymore — they re-register nerves to stop perceiving pain altogether.(3) New research is putting stimulators in at the time of spine surgery to prevent chronic pain before it even starts. If you or a loved one is silently navigating chronic pain, look beyond the pill bottle and research local pain specialists who utilize modern spinal cord stimulation. Explore trusted resources through the American Society of Pain and Neuroscience (ASPN) at https://aspnpain.com/Learn more about Dr. Falowski's practice at https://www.asclancaster.com/physicians/steven-m-falowski-md/

Lee Thomas, chair of the American Society of Travel Advisors (ASTA) talks with James Shillinglaw of Insider Travel Report at this month's ASTA Travel Advisor Conference about what ASTA's successes over the past year. Thomas, founder of NousTravel, also tells us why he got involved with ASTA and what he hopes the group will accomplish in in the next year, his second as ASTA chair. For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox. 

Dr. Andrew Fox, organizational culture expert, author, and Anglican priest, discusses the growing influence of groupthink in American society, the importance of independent thinking, and why he believes the pursuit of applause is replacing the pursuit of truth. https://drandrewfox.com/

The FiltrateJoel Topf kidneyboy.bsky.socialSpecial GuestsDr. Samir Parikh, President of the American Society of NephrologyProf. Donal Reddan, President, Irish Nephrology SocietyProf. Catherine GodsonEditing Joel TopfThe Kidney Connection written and performed by Timothy YauShow Notes Tubular SecretionsJoel Topf, the Dublin Port Greenway LinkCatherine Godson: never heard of the Dublin Port GreenwaySamir Parikh: Trinity College Dublin and specifically the Eavan Boland Library, named after the Irish poet. Donal Reddan: Something about rugby

Looking for a real community of executive assistants and business operations professionals that's free to join, supportive, and meets you where you are? ASAP Circle community manager Deanna Danger shares how she has benefited from the ASAP network and how you can, too. Recorded at EA Ignite Fall 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Step behind the curtains of the post-anesthesia care unit (PACU) in this compelling episode of the Legal Nurse Podcast. Host Pat Iyer sits down with Paul Sayeg, a seasoned registered nurse, legal nurse consultant, and expert witness, to explore the hidden world of PACU nursing, a fast-paced, detail-intensive environment where patients emerge from anesthesia at their most vulnerable. With over two decades of clinical experience, Paul shares his insights on patient monitoring, the critical role of the Aldrete and modified Aldrete scores, and the unique challenges facing nurses in this high-stakes setting. Together, they dig into the standardized tools and clinical judgment required for safe patient recovery in various settings, from hospitals to same-day surgery centers. Real-world cases and stories illustrate the life-and-death importance of nurse vigilance, thorough documentation, and seamless teamwork. The discussion also peels back the layers of system-level pressures such as "factory line healthcare," that can contribute to liability risks and medical errors. Listeners will gain a valuable perspective on how a healthy PACU culture supports early intervention and patient safety, and how expert witnesses piece together complex cases using standards published by the American Society of Peri Anesthesia Nurses (ASPAN). Whether you're a legal nurse consultant, healthcare professional, or simply curious about what happens after surgery, this episode delivers a candid look at the science, systems, and human factors behind successful post-anesthesia care. What You'll Learn in This Episode on Behind the Curtain: PACU Nursing, Complications, and Legal Risks  Here are 5 discussion questions answered in the podcast: What are the different settings in which post-anesthesia care is delivered, and how do patient acuity and procedure type influence these settings? How does the Aldrete score assist nurses in post-anesthesia care, and what are its key assessment areas? In what ways can documentation errors, such as missing vital signs, impact the accuracy of the Aldrete score and patient safety? What is the significance of the modified Aldrete score, and how has it evolved to better reflect current anesthesia practices? How do standards of care published by organizations like ASPAN influence clinical practice and legal nurse consulting? Get the free transcripts and also learn about other ways to subscribe. Go to Legal Nurse Podcasts subscribe options by using this short link: http://LNC.tips/subscribepodcast. https://youtu.be/RRAvj91rV-c Your Presenter for Behind the Curtain: PACU Nursing, Complications, and Legal Risks  Pat Iyer Pat Iyer is a seasoned legal nurse consultant and business coach, renowned for her expertise in guiding new legal nurse consultants to successfully break into the field. As the host of the Legal Nurse Podcast, Pat addresses critical challenges that legal nurse consultants face, such as difficulty in landing clients and a lack of response from attorneys. Through her insightful episodes, she emphasizes the importance of effectively communicating one's value to potential clients. With a wealth of experience, Pat has empowered countless consultants to overcome these hurdles and thrive in their careers. Connect with Pat Iyer by email at patiyer@legalnusebusiness.com Paul Sayegh Three nouns: I'm a nurse, traveler, and baker.Background: Paul Sayegh is a Registered Nurse with over two decades of Clinical experience, primarily in pre-operative care and the PACU at an academic medical center in San Francisco. He brings a perioperative perspective to his work as a legal nurse consultant and expert witness, with a focus on communication, transitions of care, and patient safety. When he's not on this podcast, Paul is caring for patients in pre-op and PACU, traveling whenever he can, and spending time in the kitchen baking for friends, family, and colleagues. Connect with Paul Sayegh by email at paulsayeghrnbsn@gmail.com

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.

A 25-year-old pregnant woman presents with a 1-day history of progressive pain and swelling. The foot is cold, pulseless and neurologic function is deteriorating by the hour. Imaging shows a massive iliofemoral DVT. Now both the limb and the pregnancy are threatened. Do you anticoagulate, thrombolyse or operate? Join us as we break down the management and decision making behind this rare but devastating case.Hosts:·      Christian Hadeed -PGY 4 General Surgery, Brookdale Hospital Medical Center·      Paul Haser -Division Chief, Vascular Surgery, Brookdale Hospital Medical Center·      Andrew Harrington, Vascular surgery, Brookdale Hospital Medical Center·      Lucio Flores, Vascular surgery, Brookdale Hospital Medical CenterLearning objectives:-       Recognize the clinical presentation and pathophysiology of phlegmasia cerulea dolens-       Describe how pregnancy affects decision making in patients with phlegmasia and venous thromboembolic disease-       Discuss the goals of treatment for patients with DVT's and identify when operative intervention is indicated-       Describe the sequelae of DVT's and how this relates to post thrombotic syndrome-       Review the indications, risks, and limitations of anticoagulation, catheter-directed thrombolysis, thrombectomy, and fasciotomy in the management of DVT and phlegmasia.-       Explain the role of IVUS in managing venous thromboembolic disease and May Thurner syndromeReferences:-       Vedantham, S., Goldhaber, S. Z., Julian, J. A., Kahn, S. R., Jaff, M. R., Cohen, D. J., Magnuson, E., Razavi, M. K., Comerota, A. J., Gornik, H. L., Murphy, T. P., Lewis, L., Duncan, J. R., Nieters, P., Derfler, M. C., Filion, M., Gu, C.-S., Kee, S., Schneider, J., … Kearon, C. (2017). Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. New England Journal of Medicine, 377(23), 2240–2252. https://doi.org/10.1056/NEJMoa1615066-       Gomes, M. S., Guimarães, M., & Montenegro, N. (2019). Thrombolysis in pregnancy: A literature review. Journal of Maternal-Fetal & Neonatal Medicine, 32(14), 2418–2428. https://doi.org/10.1080/14767058.2018.1438402-       Mangla, A., & Hamad, H. (2023). May-Thurner syndrome. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554377/-       Bates, S. M., Rajasekhar, A., Middeldorp, S., McLintock, C., Rodger, M. A., James, A. H., et al. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Advances, 2(22), 3317–3359. https://doi.org/10.1182/bloodadvances.2018024802-       Kahn, S. R., Comerota, A. J., Cushman, M., Evans, N. S., Ginsberg, J. S., Goldenberg, N. A., et al. (2014). The postthrombotic syndrome: Evidence-based prevention, diagnosis, and treatment strategies. Circulation, 130(18), 1636–1661. https://doi.org/10.1161/CIR.0000000000000130 https://pubmed.ncbi.nlm.nih.gov/25246013/Sponsor URL: https://www.goremedical.com/If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

My interview with Steven begins at 28 minutes Watch and Subscribe to 6 Questions with Steven Beschloss Read and Subscribe to Steven Beschloss Writer, journalist, editor, filmmaker, professor For more than four decades, Steven Beschloss has created award-winning stories, as a writer, journalist, editor and filmmaker. Consistent in this work is a passion for writing and a belief in the transformative power of story. As a writer and journalist -- from the U.S. and Europe -- his writing on international and urban affairs, politics, economics, education, art and culture has been published by The New Yorker,  The Washington Post, The New York Times, The New Republic, Smithsonian, The Chicago Tribune, The Wall Street Journal, Parade Magazine, National Geographic, The Economist Intelligence Unit and dozens of other print and online outlets. He's been nominated for a Pulitzer Prize, selected Journalist of the Year in Virginia, and honored with a magazine writing award by the American Society of Journalists and Authors. He is the author of the narrative book, The Gunman and His Mother: Lee Harvey Oswald, Marguerite Oswald and The Making of an Assassin, a bestselling Amazon Kindle Single and newly updated and published by Open Road Media. He is also the co-author of Adrift: Charting Our Course Back to a Great Nation (Prometheus Books), a featured guest on MSNBC, Fox Business and NPR, and he writes and publishes America, America, a popular Substack newsletter focused on politics and society, democracy and justice. Beschloss is also an adjunct professor at New York University's Arthur L. Carter Journalism Institute. He was previously a professor of practice at Arizona State University, where he founded and directed the Narrative Storytelling Initiative and worked at the College of Global Futures and the Walter Cronkite School of Journalism and Mass Communication. At ASU, he also led narrative development, serving under the president's office. In addition to his work as a journalist, writing and editing for magazines and newspapers, Beschloss has taken on various roles as a scriptwriter, producer and director for film and television. His projects have included documentary and fiction films for European television, such as The Miracle, shot in Saint Petersburg, Russia, for the French-German ARTE channel and first screened at the Pompidou Centre in Paris. In 2003, he co-wrote and co-produced Paris, a noir thriller shot in Los Angeles and Las Vegas that premiered in competition at the Tribeca Film Festival, was acquired by 20th Century Fox Home Entertainment, sold to more than 20 countries, and aired for nearly two years on the Showtime movie channels. A Chicago native and married father of two daughters, Beschloss has lived and worked in New York, London, Helsinki, Moscow and Los Angeles.  He is a graduate of Haverford College, earned his master's degree at Northwestern University's Medill School of Journalis On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Listen rate and review on Apple Podcasts Listen rate and review on Spotify Pete On Instagram Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on Twitter Pete Personal FB page Stand Up with Pete FB page Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo All things Jon Carroll  Buy Ava's Art  Subscribe to Piano Tuner Paul Paul Wesley on Substack Listen to Barry and Abigail Hummel Podcast Listen to Matty C Podcast and Substack Follow and Support Pete Coe Hire DJ Monzyk to build your website or help you with Marketing

Join us in this episode as we explore the evolving field of cardiovascular medicine with Michael S. Sacks, Professor and Director of the James T. Willerson Center for Cardiovascular Modeling and Simulation at the University of Texas at Austin. As a leading expert in cardiovascular modeling, Professor Sacks focuses on developing patient-specific, simulation-based technologies that improve our understanding of heart and heart valve disease. What's his goal? To advance treatment strategies by helping physicians better predict outcomes and design therapies tailored to individual patients… Click play to learn about: The two major problems with valve therapy. How computational modeling is transforming the diagnosis and treatment of heart disease. Why patient-specific simulations may improve surgical planning and clinical outcomes. The limitations of current valve replacement technologies. Professor Sacks has held numerous leadership roles throughout his distinguished career, including serving as Technical Editor of the Journal of Biomechanical Engineering. He is an inaugural Fellow of the Biomedical Engineering Society, a Fellow of the American Society of Mechanical Engineers, and a Fellow of the American Institute for Medical and Biological Engineering. His honors include the Van C. Mow Medal from the ASME Bioengineering Division, the University of Pittsburgh Chancellor's Distinguished Research Award, the Richard Skalak Distinguished Lectureship from Columbia University, and the SKT Lectureship from the City College of New York. In 2006, he was recognized as one of Scientific American's 50 Leaders in Science and Technology. Connect with Professor Sacks:  LinkedIn University of Texas Profile  Google Scholar Profile Willerson Center for Cardiovascular Modeling and Simulation Oden Institute for Computational Engineering & Sciences

Can I restart my GLP-1? The answer is yes — but it requires a strategic plan.  In this episode I'm walking you through exactly what happens to your body when you restart a GLP-1, why the timing of your break matters more than you think, how to restart safely without landing yourself in misery, the biggest mistakes I see patients make, and how to get back on track without shame or guilt. Restarting doesn't have to mean starting completely over. But how you restart matters. Listen now!   Episode Highlights: Why restarting at your previous dose will make you seriously sick What happens to your hunger, cravings, and fullness signals when you restart How long you've been off determines your restart dose The critical question that changes everything: weeks vs. months off Why weight regain after stopping is biology, not failure 3 practical strategies to minimize side effects and rebuild tolerance How to stay mentally on track without shame or comparison   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

PAN lanza carta disparatada después del evento de la American Society con Salinas Pliego: JacarandaEnlace para apoyar vía Patreon:https://www.patreon.com/julioastilleroEnlace para hacer donaciones vía PayPal:https://www.paypal.me/julioastilleroCuenta para hacer transferencias a cuenta BBVA a nombre de Julio Hernández López: 1539408017CLABE: 012 320 01539408017 2Tienda:https://julioastillerotienda.com/ Hosted on Acast. See acast.com/privacy for more information.

Dr. Eric Winer a past President of the American Society of Clinical Oncology speaks with current ASCO President Dr. Elizabeth Mittendorf about the developments revealed at this annual worldwide conference. Yale Cancer Center Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine.The discussion focused on the following abstracts:·      Abstract 7512o   Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32).o   The progression-free survival (PFS) benefits observed in the trial support further evaluation of the quadruplet in a phase 3 study compared with other novel combination regimens in NDMM.·      Abstract 6505o   Revumenib (Revuforj) maintenance therapy after allogeneic stem cell transplantation showed feasibility in a heavily pretreated cohort of patients with acute myeloid leukemia (AML).o   Outcomes appeared favorable vs historical cohorts, supporting prospective assessment of maintenance menin inhibition among those with AML.·      Abstract 1503o   In a retrospective analysis of electronic medical records for 293 patients who received CAR T-cell therapy for lymphoma (n = 175), multiple myeloma (n = 106), or B-cell acute lymphoblastic leukemia (n = 12), outpatient monitoring was associated with significantly fewer hospital days without increased emergency department visits or 30-day mortality.o   These findings show the potential for lower healthcare utilization for patients who receive CAR T-cell therapy in the outpatient setting.·      Abstract LBA7000o   Adding tafasitamab (Monjuvi) and lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) significantly improved PFS vs R-CHOP alone among those with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the phase 3 frontMIND trial (NCT04824092).o   The data may support tafasitamab plus lenalidomide and R-CHOP as a potential new standard of care in the frontline treatment of patients with cell-of-origin subtypes of high-risk DLBCL.References Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: phase 1/2 BelaDRd study. J Clin Oncol. 2026;44(suppl 16):7512. doi:10.1200/JCO.2026.44.16_suppl.7512 Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505 Bowen SG, Abdallah N, Pritchett JC, et al. Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies. J Clin Oncol. 2026;44(suppl 16):1503. doi:10.1200/JCO.2026.44.16_suppl.1503 Lenz, G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000

This week, we return to a lively conversation with Dr. Soong-Chan Rah, hosted by Octavio and Claire back in 2020. Here, they consider the need for the North American church to break free from Western cultural captivity and embrace the diversity of our communities in our gathered worship and theology. Soong-Chan emphasizes the importance of diversity, community, and authentic cultural expression in faith communities. If this conversation piques your interest, consider joining him in the classroom this summer. He will be teaching "Cultural Intelligence for a Changing Church" from July 6-10. Soong-Chan's BioSoong-Chan Rah is the Robert Boyd Munger Professor of Evangelism and Church Renewal at Fuller Theological Seminary. He holds a ThD from Duke Divinity School, with a primary field of study in theology and ethics, and a secondary field of study in American evangelical history. He also holds an MDiv and a DMin, with a concentration in urban ministry leadership, from Gordon-Conwell Theological Seminary, as well as a ThM from Harvard University, with a thesis on the immigrant church.Dr. Rah has authored or co-authored over a half-dozen books, which have won many awards. These include The Next Evangelicalism: Freeing the Church from Western Cultural Captivity(IVP, 2009); Many Colors: Cultural Intelligence for a Changing Church (Moody, 2010); Prophetic Lament: A Call for Justice in Troubled Times (IVP, 2015); Return to Justice: Six Movements that Reignited Our Contemporary Evangelical Conscience (with Gary Vanderpol; Brazos, 2016); Unsettling Truths: The Ongoing, Dehumanizing Legacy of the Doctrine of Discovery (with Mark Charles; IVP, 2019); and Forgive Us: Confessions of a Compromised Faith (with Mae Elise Cannon, Lisa Sharon Harper, and Troy Jackson; Zondervan, 2014).Dr. Rah is an ordained pastor in the Evangelical Covenant Church and a member of the Academy for Evangelism in Theological Education, the American Academy of Religion, and the American Society of Missiology. He speaks on the topics of the witness of the church, cross-cultural ministry, and social justice at a wide range of academic conferences, seminaries, Christian colleges, local churches, denominational gatherings, and ministry conferences across the United States and around the world.Regent College PodcastThanks for listening. Please like, rate and review us on your podcast platform of choice and share this episode with a friend. Follow Us on Social MediaFacebookInstagramYoutubeKeep in TouchRegent CollegeSummer ProgramsRegent College Newsletter

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and insightful sessions. In this week’s episode of "The Top Line," Fierce Biotech and Fierce Pharma’s Darren Incorvaia, Zoey Becker and Angus Liu break down the biggest takeaways from their weekend of reporting live from the Windy City. From “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset, ASCO 2026 reflected new and continuing trends within the evolving state of cancer care today. To learn more about the topics in this episode: ASCO: Revolution Medicines confident in RAS leadership as rivals square up ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary See omnystudio.com/listener for privacy information.

This episode explores how America's interstate highway system and the rise of the algorithmic internet followed remarkably similar paths, both promoted as revolutionary tools of connection, freedom, and democratization before ultimately accelerating fragmentation, inequality, isolation, and centralized control. Drawing from the article “The false promise of human connection from the interstate highway system to the algorithmic internet,” the episode examines how highways physically divided urban communities like Milwaukee's Bronzeville under the banner of modernization, while digital platforms later reproduced many of the same divisions through algorithms built around engagement, outrage, and corporate consolidation. The conversation traces the parallels between suburban expansion and platform monopolies, the erosion of public and civic spaces, and the growing dependence on infrastructure systems that increasingly function less as democratic commons and more as privately controlled toll roads shaping modern American life.

En entrevista para MVS Noticias con Luis Cárdenas, Larry Rubin, presidente de la American Society of México, habló sobre T-MEC va más allá de lo comercial.See omnystudio.com/listener for privacy information.

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics' Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso's clinical trial in China will hold up in a global population.Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China's Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We'll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

O Congresso da ASCO — American Society of Clinical Oncology — reúne por estes dias cerca de 40 mil especialistas e acaba de anunciar resultados muito importantes ao nível do tratamento do cancro no pâncreas, no pescoço e na cabeça. A oncologia tem feito avanços muito significativos ao nível das terapias e dos medicamentos. Falamos neste episódio com o Dr. Diogo Alpuim Costa, que está em Chicago neste congresso de oncologia.See omnystudio.com/listener for privacy information.

Have you used "the steeple" in meetings with executives? Learn what this means and so much more from body language expert Janine Driver. Recorded at EA Ignite Fall 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Sybil Derrible, professor of urban engineering at the University of Illinois, Chicago, and author of the popular science title ‘The Infrastructure Book: How Cities Work and Power Our Lives,' joins the program to discuss the state of global infrastructure. He is also a fellow of the American Society of Civil Engineers, and was a lead author on the United Nations Environmental Program Seventh Global Environment Outlook (GEO-7). Derrible invites your questions and comments. He can be reached at derrible@uic.edu. (06/2026)

Sybil Derrible, professor of urban engineering at the University of Illinois, Chicago, and author of the popular science title ‘The Infrastructure Book: How Cities Work and Power Our Lives,' joins the program to discuss the state of global infrastructure. He is also a fellow of the American Society of Civil Engineers, and was a lead author on the United Nations Environmental Program Seventh Global Environment Outlook (GEO-7). Derrible invites your questions and comments. He can be reached at derrible@uic.edu. (06/2026)

Sybil Derrible, professor of urban engineering at the University of Illinois, Chicago, and author of the popular science title ‘The Infrastructure Book: How Cities Work and Power Our Lives,' joins the program to discuss the state of global infrastructure. He is also a fellow of the American Society of Civil Engineers, and was a lead author on the United Nations Environmental Program Seventh Global Environment Outlook (GEO-7). Derrible invites your questions and comments. He can be reached at derrible@uic.edu. (06/2026)

Eleonora Teplinsky, MD, is the head of breast and gynecologic medical oncology and Valley-Mount Sinai Comprehensive Cancer Center in Paramus, New Jersey, as well as an ASCO breast cancer expert. She explained the most compelling research results on breast cancer presented at the 2026 American Society of Clinical Oncology Annual Meeting. Listen to the episode to hear Dr. Teplinsky explain: the importance of the OPTIMA study, as well as her caveats about the results the latest results from the ASCENT-04 study what progression-free survival 2 (PFS2) is and how it helps doctors decide which treatments should be given first what we do and don't know about GLP-1 medicines and cancer

At the 2026 American Society of Clinical Oncology Annual Meeting poster session, we asked four scientists to discuss their research. Listen to the episode to hear: Peter Stanfield, of the University of Wisconsin, explains his research on cancer screening rates in transgender and gender-diverse people. Nico Gotera, of the University of Texas Health Science Center, explains research on GLP-1 medicines and rates of breast cancer in postmenopausal women. Anna Tanasijevic, of the Dana-Farber Cancer Institute, explains research on how much cancer survivors exercise. Xianghui Zou, of NYU Langone Health, explains research on the timing of immunotherapy infusions for people with early-stage triple-negative breast cancer.

In a special cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of chimeric antigen receptor (CAR) T-cell–related lymphomas developing in the gastrointestinal (GI) tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. Listen below or via your favorite podcast platform.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

You stopped your GLP-1 and now you're wondering can I just restart where I left off? Why am I so hungry again? Why are the side effects back? Did the medication stop working? These are questions I hear all the time in my practice. And the answer is not as simple as picking back up where you stopped. In this episode I am walking you through exactly what happens biologically when you stop a GLP-1, why restarting feels different than when you first started, how to restart safely, the common mistakes I see patients make, and how to get back on track mentally without shame. A pause does not erase your progress. But how you restart matters more than you think. Listen now! Episode Highlights: Why stopping your medication is not failure and why your biology is not your weakness What actually happens to your hunger, cravings, and fullness signals when you go off GLP-1s Why restarting at your old dose can land you in the emergency room How long is too long to be off and what dose to restart at based on your break The 3 most common restart mistakes  Practical tips to minimize side effects and rebuild tolerance the right way How to stay mentally on track without shame or comparison to your first journey Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

At the 2026 American Society of Clinical Oncology Annual Meeting, Dr. Jennifer Ligibel, director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at the Dana-Farber Cancer Institute, presented early results from the Breast Cancer Weight Loss (BWEL) study. The findings showed that among women with early-stage breast cancer, losing weight led to better physical and mental health, and also helped ease fatigue. Listen to the episode to hear Dr. Ligibel explain: the design of the BWEL study why the women in the study had to have hormone receptor-positive, HER2-negative or triple-negative breast cancer the next steps for the study

In this episode of Crime and the Courtroom, John Collins reflects on recent presentations at the American Society of Crime Laboratory Directors Symposium and the Association of Firearm and Toolmark Examiners conference before turning his attention to the central themes of his new book, "Valid Comparisons: The Forensic and Judicial Examination of Stochastic Patterns." Collins examines how misunderstandings surrounding the 1993 Daubert decision shaped decades of debate within forensic science and contributed to what he describes as the "Daubert contagion"—a movement that fostered excessive doubt about the scientific foundations of many forensic disciplines. Drawing on his experience as a forensic scientist, laboratory director, and expert witness, Collins argues that pattern comparison disciplines such as firearm identification, toolmark examination, and latent print analysis remain scientifically valid despite their perception as being highly interpretive. He challenges the notion that instrument-based disciplines are somehow free from subjectivity, emphasizing that all scientific conclusions require interpretation and professional judgment. The episode offers a thoughtful discussion of scientific validity, expert testimony, error, confidence, and the continuing role of forensic science in helping courts answer difficult questions in the pursuit of justice. Season:   6 Episode:  113 Duration:  1:00:24 YOUTUBE CHANNELS Main Podcast Channel Highlights Channel REFERENCED RESOURCES None ABOUT YOUR HOST John Morrey Collins is a leadership and expertise coach specializing in working with clients in authoritative, high-stakes occupations, but with a primary emphasis on serving leaders, professionals, and organizations that support our complicated systems of criminal and civil justice. John started his private practice, Critical Victories, in 2013 after retiring his award-winning, 20-year career as a forensic laboratory scientist and executive administrator, having served as the Director of Forensic Science for the State of Michigan. His forensic technical expertise was in the examination and testing of firearms and firearm-related evidence, having provided expert courtroom testimony in approximately 130 criminal trials, including death penalty cases and Daubert hearings. John is also the author of three books on forensic science and criminal justice reform. In 2022, he released his fourth book, "The New Superior – A Better Way to Be the One in Charge," which is available in print and audio. John's many career highlights include his part in the forensic investigation of the Atlanta serial bombings, which included the bombing of the 1996 Olympics in Atlanta, as well as his 2013 participation in a historic meeting with the US Attorney General and other firearm experts to discuss the Sandy Hook Elementary School shooting. John has a master's degree in organizational management and is formally certified as a Senior HR Professional by the Society for Human Resource Management (SHRM). In 2012, John was trained as a professional coach by the College of Executive Coaching, and he became certified as a Gallup Strengths Coach in 2022. He lives and works near Detroit, Michigan. For more books and other information, please visit www.criticalvictories.com.

No Shade, No Standard: America's Heat Safety Gap As extreme heat intensifies, outdoor and factory workers are facing risks their jobs were never built to handle. With protections still varying by state, advocates are pushing for updated national standards on shade, water, rest and retaliation-free reporting. Guests:  Pamela Walaski, president, Board of Directors of the American Society of Safety Professionals Katelyn Parady, development and strategic programs liaison, National Council for Occupational Safety and Health Host: Marty Peterson Producers: Amirah Zaveri and Polly Hansen Linktr.ee | Apple Podcasts | YouTube | SpotifyFacebook: @ViewpointsOnlineX: @viewpointsradioInstagram: @viewpointsradioFull ArchiveContact UsAffiliates & National Syndication Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Results from the OPTIMA trial suggest that people with early-stage hormone receptor-positive, HER2-negative breast cancer that seems to have a high risk of recurrence based on clinical features — like a high number of positive lymph nodes — may be able to safely skip chemotherapy if they have a low Prosigna risk of recurrence score. The findings were presented at the 2026 American Society of Clinical Oncology Annual Meeting. Iain MacPherson, professor of breast oncology at the University of Glasgow, was chief investigator of the study. Listen to the episode to hear Dr. MacPherson explain: the design and results of the OPTIMA study why he thinks the trial results are groundbreaking whether or not the results apply to men with this type of breast cancer

Money Anxiety: From Family Lessons To The Money Habits We Lean On Money decisions are rarely just about math. Financial expert Lev Mandel explains how early family lessons, anxiety and repeated habits can shape the way people view money and approach these conversations, and why understanding those patterns can help build a healthier relationship with finances over time. Guest: Lev Mandel, financial expert, author, Money Is Weird. Host: Gary Price Producer: Amirah Zaveri No Shade, No Standard: America's Heat Safety Gap As extreme heat intensifies, outdoor and factory workers are facing risks their jobs were never built to handle. With protections still varying by state, advocates are pushing for updated national standards on shade, water, rest and retaliation-free reporting. Guests:  Pamela Walaski, president, Board of Directors of the American Society of Safety Professionals Katelyn Parady, development and strategic programs liaison, National Council for Occupational Safety and Health Host: Marty Peterson Producer: Amirah Zaveri and Polly Hansen Linktr.ee | Apple Podcasts | YouTube | SpotifyFacebook: @ViewpointsOnlineX: @viewpointsradioInstagram: @viewpointsradioFull ArchiveContact UsAffiliates & National Syndication Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Megan-Claire Chase, known as Warrior Megsie on social media, was one of the speakers at the ASCO Voices session. In her talk, she explained how her views on clinical trials shifted after she was diagnosed with breast cancer. Listen to the episode to hear Megsie explain: some of the reasons why the Black community distrusts the medical system why she didn't want to be part of a clinical trial how her feelings changed after she suffered rare, debilitating side effects from treatment why she became an outspoken advocate

FCC Chairman Brendan Carr joins after Disney filed early license renewal applications for its broadcast stations at the agency's request. Then, Erin Brockovich discusses the environmental concerns around the data center buildout and a new map she created to help track them. Plus, we take a look at what to expect from the American Society of Clinical Oncology's annual meeting, which kicks off today. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Julia T. Woodward, Ph.D. is a Professor in the Departments of Psychiatry & Behavioral Sciences and Obstetrics & Gynecology in the Duke University Health System. She has directed the Patient Support Program at the Duke Fertility Center for over 20 years. Clinically, she specializes in working with patients facing infertility, pregnancy loss, third-party reproduction, fertility preservation, and perinatal mood disorders. She trains Clinical Psychology PhD students, Predoctoral Interns, and Postdoctoral Fellows as well as REI Fellows and OBGYN residents in the psychosocial aspects of reproductive medicine. She has held multiple committee leadership positions in the Mental Health Professional Group of the American Society for Reproductive Medicine, is the current Chair of the Scientific Development Committee and previously served on the Executive Council for the Society for Assisted Reproductive Technology (SART). She serves as an Associate Editor for Human Reproduction. She publishes regularly and lectures internationally on the psychosocial aspects of reproductive medicine, integration of mental health services into fertility care teams, and later-life parenting. CONNECT WITH DVORA ENTIN: Website: https://www.dvoraentin.com/ Instagram: https://www.instagram.com/dvoraentin YouTube: https://www.youtube.com/@misconceptionspodcast  

Cinematographer Steven Poster, ASC has spent five decades behind the camera, and helped lead the industry from film into digital along the way. He's shot for Ridley Scott, Steven Spielberg, and John Carpenter, and served as president of both the American Society of Cinematographers and the International Cinematographers Guild. He also oversaw one of the first digital intermediates ever finished, lensed the cult classic Donnie Darko, and shot the iconic "Like a Prayer" video for Madonna.We explore his origins learning his craft from a Chicago newsreel shooter, his career-long drive to innovate new technologies and techniques, his approach to daylight and diffusion, and why he thinks DPs shouldn't operate their own cameras.Grab Sweet Spot, my free exposure tool that gives you simple, scene-accurate metering in stops, for every camera: https://cullenkellycolor.com/toolkit/sweet-spot. Steven called it a “game-changer” after using it on his most recent project.Chapters 0:00 — Welcome0:24 — Chicago beginnings and union politics5:55 — Seeing digital coming: NHK, Sony, and the HD experiments9:51 — Stuart Little 2 and one of the first digital intermediates14:00 — Three weeks on the soccer field: working blind20:22 — Donnie Darko: 22 days, anamorphic, and an untested film stock27:35 — Shooting daylight: polarizers and diffusion30:34 — Coming up with Vilmos Zsigmond33:42 — Blade Runner: the tunnel shot44:00 — Collaborating with Richard Kelly on Donnie Darko50:28 — Why a DP shouldn't operate their own camera51:55 — Working with Sophia Loren56:09 — Lessons from Ridley Scott59:51 — Core principles: don't be afraid1:02:30 — Next-generation display technology

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques. Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds. This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll Pearls Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan. The “Power of Zero” vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss. CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a “game changer,” allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis. CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety. Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify “subvisual” plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes. Show Notes How has the role of CCTA changed compared to traditional functional testing? Historically, stress testing answered “is there ischemia today?”, which often reflects late-stage disease. CCTA identifies disease across the entire spectrum, asking “is there atherosclerosis and how much plaque is present?”. Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography. Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.” What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter? CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR. It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but “extensive” (P4) plaque burden is considered high risk and warrants aggressive risk factor modification. How is CT-FFR calculated, and when is it most useful in clinical practice? CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia. It is often used for intermediate lesions (40–90% stenosis) to predict if they are  ischemia-producing, guiding the decision whether to proceed with invasive angiography.  The assumptions necessary for this computational modeling may not apply well to patients with microvascular dysfunction, significant myocardial scar or prior infarction, or ventricular hypertrophy. Still, data indicate that CT-FFR performs similarly to PET in predicting hemodynamically significant lesions.  CT-FFR performs well at the extremes (either clearly normal or clearly abnormal). Accuracy dips, however, in the intermediate range (~0.75-0.80), where decision-making is most critical. In this grey zone, additional factors can help guide the approach, including the amount of myocardium supplied, translesional gradient, and plaque features.   CT-FFR has not been validated in distal segments, stented segments, heavily calcified coronary arteries, or in patients with severe aortic stenosis. Caution with CT-FFR should be utilized in very calcified coronary segments.  What is AI-based quantitative plaque analysis (QCPA), and what metrics are ready for clinical use? This is potentially a paradigm shift, moving away from stenosis-centric thinking to a more disease burden and plaque biology focus. QCPA uses deep learning algorithms to automatically segment the vessel wall and quantify plaque volume in mm³. Ready for “prime time” metrics include: Total Plaque Volume (TPV), non-calcified plaque volume, and Low-Attenuation Plaque (LAP) burden. Can serial CCTA be used to monitor the effectiveness of medical therapies like statins? While not yet a routine guideline-driven practice, trials like PARADIGM and EVAPORATE show that therapies can stabilize plaque; notably, CCTA is better for monitoring than CAC scores, which can be misleading as statins often increase plaque calcification as part of the stabilization process. There are no randomized trials that serial CCTAs improve outcomes. Cost and radiation exposure will be notable limitations. Serial scan timing, scan acquisition and interpretation standardization would be key. Dr. Gallagher notes that we are moving toward a world in which plaque burden may become a “treatment biomarker,” similar to tumor burden in oncology.  References 1. Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies: JACC State-of-the-Art Review. Abdelrahman KM, Chen MY, Dey AK, et al. Journal of the American College of Cardiology. 2020;76(10):1226-1243. doi:10.1016/j.jacc.2020.06.076. 2. Non-Invasive Imaging in Coronary Syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Edvardsen T, Asch FM, Davidson B, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2022;35(4):329-354. doi:10.1016/j.echo.2021.12.012. 3. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053. 4. Contemporary, Non-Invasive Imaging Diagnosis of Chronic Coronary Artery Disease. van der Bijl P, Gulati M, Saraste A, et al. Lancet (London, England). 2025;406(10519):2577-2587. doi:10.1016/S0140-6736(25)01586-7. 5. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. 6. Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography: The ACCURATE-CT Study. Li C, Hu Y, Jiang J, et al. JACC. Cardiovascular Interventions. 2024;17(17):1980-1992. doi:10.1016/j.jcin.2024.06.027. 7. Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization. Sato Y, Motoyama S, Miyajima K, et al. JACC. Cardiovascular Imaging. 2024;17(3):284-297. doi:10.1016/j.jcmg.2023.07.013. 8. Clinical Use of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Expert Consensus by an International Working Group. Tang CX, Leipsic JA, Nørgaard BL, et al. European Radiology. 2026;:10.1007/s00330-025-12313-6. doi:10.1007/s00330-025-12313-6. 9. Diagnostic accuracy of computed tomography–derived fractional flow reserve: a systematic review. Cook CM, Petraco R, Shun-Shin MJ, et al. JAMA Cardiol. 2017;2(7):803-810. Doi:10.1001/jamacardio.2017.1314 10. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). Nørgaard BL, Leipsic J, Gaur S, et al. J Am Coll Cardiol. 2014;63(12):1145-1155. Doi:10.1016/j.jacc.2013.11.043 11. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. Driessen RS, Danad I, Stuijfzand WJ, et al. J Am Coll Cardiol. 2019;73(2):161-173. Doi:10.1016/j.jacc.2018.10.056. 12. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study. Douglas PS, De Bruyne B, Pontone G, et al. J Am Coll Cardiol. 2016;68(5):435-445. Doi:10.1016/j.jacc.2016.05.057. 13. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. Douglas PS, Nanna MG, Kelsey MD, et al; PRECISE Investigators. JAMA Cardiol. 2023;8(10):904-914. Doi:10.1001/jamacardio.2023.2595. 14. Diagnostic and clinical value of FFRCT in stable chest pain patients with extensive coronary calcification: the FACC study. Mickley H, Veien KT, Gerke O, et al. JACC Cardiovasc Imaging. 2022;15(6):1046-1058. doi:10.1016/j.jcmg.2021.12.010. 15. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Williams MC, Kwiecinski J, Doris M, et al. Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720. 16. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. Nurmohamed NS, Bom MJ, Jukema RA, et al. JACC. Cardiovascular Imaging. 2024;17(3):269-280. doi:10.1016/j.jcmg.2023.05.020. 17. Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry. Dundas J, Leipsic J, Fairbairn T, et al. Circulation. Cardiovascular Imaging. 2024;17(3):e016143. doi:10.1161/CIRCIMAGING.123.016143. 18. Prognostic Value of AI-Based Quantitative Coronary CTA vs Human Reader-Based Visual Assessment: Results From the CONFIRM2 Registry. van Rosendael A, Nakanishi R, Bax JJ, et al. JACC. Cardiovascular Imaging. 2026;19(3):345-359. doi:10.1016/j.jcmg.2025.09.021.13. Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk: JACC Review Topic of the Week. Tan N, Dey D, Marwick TH, Nerlekar N. Journal of the American College of Cardiology. 2023;81(9):913-923. doi:10.1016/j.jacc.2022.12.021. 19. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: Final Results of the EVAPORATE Trial. Budoff MJ, Bhatt DL, Kinninger A, et al. European Heart Journal. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. 20. Coronary CT Angiography Evaluation With Artificial Intelligence for Individualized Medical Treatment of Atherosclerosis: A Consensus Statement From the QCI Study Group. Schulze K, Stantien AM, Williams MC, et al. Nature Reviews. Cardiology. 2026;23(2):100-115. doi:10.1038/s41569-025-01191-6.

In this episode of The 20/20 Podcast, Dr. Harbir Sian sits down with internationally recognized dry eye expert and ophthalmologist Dr. Laura Periman from Seattle, Washington. Rather than focusing on rigid protocols or step-by-step treatment algorithms, the conversation zooms out to explore how clinicians should think about dry eye disease in an era of rapidly evolving science.Dr. Periman explains why “dry eye” is an oversimplified label for an incredibly complex and multifactorial disease process involving inflammation, neurosensory dysfunction, pain pathways, microbiome disruption, blink mechanics, ocular surface disease, and more. She describes the field as a constantly expanding landscape where curiosity, innovation, and questioning old assumptions are essential. The discussion dives into emerging innovations in dry eye care, including molecular therapies aimed at repairing corneal tissue, targeted approaches to recurrent corneal erosion, novel pain-signaling pathways, and therapies addressing neurosensory compromise. Dr. Periman shares insights from presenting recent dry eye innovations at the American Society of Cataract and Refractive Surgery, highlighting how advances in the field are reshaping our understanding of ocular surface disease. The conversation also explores personalized medicine in dry eye management. Rather than applying generic treatments, Dr. Periman advocates identifying the specific mechanistic contributors in each patient—whether that's Demodex, rosacea, incomplete blinking, inflammation, dysbiosis, blepharitis, or neurosensory dysfunction—and selecting targeted interventions accordingly. Finally, the episode touches on the growing importance of ocular surface optimization before refractive and cataract surgery. Dr. Periman discusses evidence suggesting that preoperative management with immunomodulators may improve surgical outcomes, patient satisfaction, and visual quality. She also challenges long-held beliefs about how quickly these therapies work, emphasizing the importance of revisiting old dogma as new evidence emerges. At its core, this episode is a reminder that the best clinicians remain curious, question assumptions, and continually evolve alongside the science.Key Moments1. “Dry eye isn't just dry eye.”Dr. Periman reframes dry eye as an enormous umbrella term covering multiple overlapping disease mechanisms, emphasizing the need for deeper thinking beyond traditional categories. 2. The future of treatment is molecular and personalized.The conversation explores emerging therapies targeting recurrent corneal erosion, connexin signaling, pain pathways, and tissue repair—pointing toward increasingly precise, individualized care. 3. Better surgical outcomes may start weeks before surgery.Dr. Periman discusses evidence supporting pre-treatment of ocular surface inflammation prior to refractive and cataract procedures, potentially improving outcomes and patient satisfaction. Guest Contact InformationDr. Laura Perimanhttps://dryeyemaster.com/Instagram: @dryeyemasterLove the show? Subscribe, rate, review & share! http://www.aboutmyeyes.com/podcast/

At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field's approach to the cancer. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Revolution's daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury's radar at this year's American Society of Clinical Oncology meeting.BioCentury's analysts also discuss a push by China hawks in Congress to get the Trump administration to invoke national security powers to narrow Chinese life sciences companies' access to U.S. markets, technology and capital; an initiative by Rep. Jake Auchincloss (D-Mass.) that seeks to modernize how clinical trials are conducted in the U.S.; and a BioCentury analysis on new antibody-drug conjugate linker techniques. This episode of the BioCentury podcast is brought to you by Jeito Capital.View full story: https://www.biocentury.com/article/659581 #Biopharma #ASCO2026 #PancreaticCancer #ClinicalTrials #ADCInnovation00:01 - Sponsor Message: Jeito Capital02:26 - ASCO Preview14:24 - U.S. China Policy22:48 - Modernizing U.S. trials27:17 - Optimizing ADC LinkersTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

If you're curious about the design principles behind the most impressive slide decks and documents, dive into this episode covering best practices from a visual communication expert. Recorded at EA Ignite Fall 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.